AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Transporter 41/14/2024 With metastatic CRC remains relatively low. Patients with metastatic CRC, however, the prognosis of patients In chemotherapy have been improving the overall survival of In Japan, cancer-related death from CRC wasĮstimated to be the most frequent cause of female cancer-relatedĭeath, and the third most frequent cause of male cancer-related Therefore, positive MCT4 expression appears to be a useful marker for tumor progression and prognosis in patients with CRC.Ĭolorectal cancer (CRC) is one of the most lethalĬancers in the world. ![]() Positive MCT4 expression was a significantly poor prognostic factor, as determined by both univariate and multivariate analyses. The survival rate of the patients who were positive for MCT4 expression was significantly lower than that of patients with negative MCT4 expression. The expression of MCT4 significantly correlated with the tumor size, depth of invasion, lymph node metastasis, distant metastasis and TNM staging. A total of 53 (50.5%) of the 105 patients with CRC were determined to have tumors positive for MCT4 expression. The relationships among the MCT4 expression, clinicopathological factors and prognosis were evaluated. ![]() Surgical specimens from 105 CRC patients were immunohistochemically stained using a polyclonal anti-MCT4 antibody. ![]() The prognostic significance of MCT4 expression has not been evaluated in patients with colorectal cancer (CRC). Monocarboxylate transporter 4 (MCT4) is one of the proton pumps exchanging the lactate through the plasma membrane. Cancer cells generally have a high rate of glycolysis and produce larger quantities of lactate as compared to the surrounding normal cells.
0 Comments
Read More
Leave a Reply. |